Cargando…

Nedosiran in primary hyperoxaluria subtype 3: results from a phase I, single-dose study (PHYOX4)

Nedosiran is an N-acetyl-D-galactosamine (GalNAc)–conjugated RNA interference agent targeting hepatic lactate dehydrogenase (encoded by the LDHA gene), the putative enzyme mediating the final step of oxalate production in all three genetic subtypes of primary hyperoxaluria (PH). This phase I study a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goldfarb, David S., Lieske, John C., Groothoff, Jaap, Schalk, Gesa, Russell, Kerry, Yu, Shuli, Vrhnjak, Blaz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10147791/ https://www.ncbi.nlm.nih.gov/pubmed/37118061 http://dx.doi.org/10.1007/s00240-023-01453-3

Ejemplares similares

Correction to: Nedosiran in primary hyperoxaluria subtype 3: results from a phase I, single-dose study (PHYOX4)
por: Goldfarb, David S., et al.
Publicado: (2023)

A Case Report of Kidney-Only Transplantation in Primary Hyperoxaluria Type 1: A Novel Approach with the Use of Nedosiran
por: Breeggemann, Matthew C., et al.
Publicado: (2023)

Primary hyperoxaluria: the pediatric nephrologist's point of view
por: Ben-Shalom, Efrat, et al.
Publicado: (2022)

A randomised Phase II/III study to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria
por: Milliner, Dawn, et al.
Publicado: (2017)

Genetic assessment in primary hyperoxaluria: why it matters
por: Mandrile, Giorgia, et al.
Publicado: (2022)

Transplantation outcomes in patients with primary hyperoxaluria: a systematic review
por: Metry, Elisabeth L., et al.
Publicado: (2021)

Primary hyperoxaluria type 1: novel therapies at a glance
por: Bacchetta, Justine, et al.
Publicado: (2022)

Determinants of Kidney Failure in Primary Hyperoxaluria Type 1: Findings of the European Hyperoxaluria Consortium
por: Metry, Elisabeth L., et al.
Publicado: (2023)

New Insights Regarding Organ Transplantation in Primary Hyperoxaluria Type 1
por: Sas, David J., et al.
Publicado: (2021)

Plasma oxalate and glycolate concentrations in dialysis patients with and without primary hyperoxaluria type 1
por: Metry, Elisabeth L, et al.
Publicado: (2023)

Long-Term Transplantation Outcomes in Patients With Primary Hyperoxaluria Type 1 Included in the European Hyperoxaluria Consortium (OxalEurope) Registry
por: Metry, Elisabeth L., et al.
Publicado: (2021)

Pilot study of reloxaliase in patients with severe enteric hyperoxaluria and hyperoxalemia
por: Pfau, Anja, et al.
Publicado: (2021)

Nephrocalcinosis is a risk factor for kidney failure in primary hyperoxaluria
por: Tang, Xiaojing, et al.
Publicado: (2014)

Primary Hyperoxaluria
por: Harambat, Jérôme, et al.
Publicado: (2011)

Randomized Clinical Trial on the Long-Term Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1
por: Hulton, Sally A., et al.
Publicado: (2021)

Successful Treatment of Primary Hyperoxaluria Type 2 with a Combined Liver and Kidney Transplant
por: Genena, Kareem M., et al.
Publicado: (2023)

ePHex: a phase 3, double-blind, placebo-controlled, randomized study to evaluate long-term efficacy and safety of Oxalobacter formigenes in patients with primary hyperoxaluria
por: Ariceta, Gema, et al.
Publicado: (2022)

Plasma Oxalate as a Predictor of Kidney Function Decline in a Primary Hyperoxaluria Cohort
por: Shah, Ronak Jagdeep, et al.
Publicado: (2020)

Development and Validation of a New Gas Chromatography–Tandem Mass Spectrometry Method for the Measurement of Enrichment of Glyoxylate Metabolism Analytes in Hyperoxaluria Patients Using a Stable Isotope Procedure
por: van Harskamp, Dewi, et al.
Publicado: (2019)

Urinary monocyte chemoattractant protein 1 associated with calcium oxalate crystallization in patients with primary hyperoxaluria
por: Wang, Xiangling, et al.
Publicado: (2020)

Primary hyperoxaluria and systemic oxalosis
por: Sriram, K., et al.
Publicado: (2007)

Enteric hyperoxaluria in chronic pancreatitis
por: Demoulin, Nathalie, et al.
Publicado: (2017)

Pyridoxine Responsiveness in a Type 1 Primary Hyperoxaluria Patient With a Rare (Atypical) AGXT Gene Mutation
por: Singh, Prince, et al.
Publicado: (2020)

Pancytopenia as a Complication of Primary Hyperoxaluria
por: Khosravi, M., et al.
Publicado: (2019)

The Struggling Odyssey of Infantile Primary Hyperoxaluria
por: Guillaume, Adrien, et al.
Publicado: (2021)

Treatment of primary hyperoxaluria type 1
por: Gupta, Asheeta, et al.
Publicado: (2022)

Improving Treatment Options for Primary Hyperoxaluria
por: Hoppe, Bernd, et al.
Publicado: (2022)

Primary hyperoxaluria: a case series
por: Rather, Jawad Iqbal, et al.
Publicado: (2023)

Natural History of Clinical, Laboratory, and Echocardiographic Parameters of a Primary Hyperoxaluria Cohort on Long Term Hemodialysis
por: Sas, David J., et al.
Publicado: (2021)

Specific populations of urinary extracellular vesicles and proteins differentiate type 1 primary hyperoxaluria patients without and with nephrocalcinosis or kidney stones
por: Jayachandran, Muthuvel, et al.
Publicado: (2020)

Bilateral nephrocalcinosis in primary hyperoxaluria type 1
por: Mansoor, C. A., et al.
Publicado: (2016)

Primary Hyperoxaluria Involving the Liver With Crystal Deposits
por: Bansal, Nalini, et al.
Publicado: (2019)

ALLN-177, oral enzyme therapy for hyperoxaluria
por: Lingeman, James E., et al.
Publicado: (2019)

Is stiripentol truly effective for treating primary hyperoxaluria?
por: Martin-Higueras, Cristina, et al.
Publicado: (2020)

Primary hyperoxaluria type 1: pathophysiology and genetics
por: Fargue, Sonia, et al.
Publicado: (2022)

Primary hyperoxaluria: the adult nephrologist's point of view
por: Moochhala, Shabbir H, et al.
Publicado: (2022)

Clinical and molecular characterization of primary hyperoxaluria in Egypt
por: Soliman, Neveen A., et al.
Publicado: (2022)

Correction to: Specific populations of urinary extracellular vesicles and proteins differentiate type 1 primary hyperoxaluria patients without and with nephrocalcinosis or kidney stones
por: Jayachandran, Muthuvel, et al.
Publicado: (2021)

Chronic liver disease and hepatic calcium-oxalate deposition in patients with primary hyperoxaluria type I
por: Recker, Pia, et al.
Publicado: (2022)

Dietary hyperoxaluria is not reduced by treatment with lactic acid bacteria
por: Siener, Roswitha, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_kq99hk15ak7316t20o5js169b9